E M H Swiss Medical Publishers Ltd

SHERPA: Unknown

People

  1. Levine
    Levine
  2. Koche
    Koche
  3. Yang
    Yang

Groups

  1. Adult Leukemia (11)
  2. Center for Hematologic Malignancies (11)
  3. Center for Molecular Imaging and Biotechnology (11)
  4. Department of Medicine (11)
  5. Executive Committee, Center for Hematologic Malignancies (11)
  6. GSK Faculty (11)
  7. Hematologic Malignancies, Division of (11)
  8. Human Oncology and Pathogenesis Program (11)
  9. Sloan Kettering Institute Postdocs (1)
Search Within
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (11)
Groups
  1. Adult Leukemia (11)
  2. Center for Hematologic Malignancies (11)
  3. Center for Molecular Imaging and Biotechnology (11)
  4. Department of Medicine (11)
  5. Executive Committee, Center for Hematologic Malignancies (11)
  6. GSK Faculty (11)

More Groups

People
  1. Ross Levine (11)
  2. Li Yang (3)
  3. Richard Koche (3)
  4. Maria Kleppe (1)
  5. Matthew Keller (1)
  6. Sophia Chiu (1)
Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (3)
  6. 2018 (1)
Publications
  1. Swiss Medical Weekly (11)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Role of ERK1/2 kinases in megakaryopoiesis, thrombopoiesis, platelet function and thrombosis in myeloproliferative neoplasms
    Meeting Abstract

    Albrecht, C.; Stivala, S.; Vokalova, L.; Knopp, T.; Angelillo-Scherrer, A.; Levine, R.; Neel, B.; Meyer, S.
    Swiss Medical Weekly (2023)

    Fulltext@MSK | Save
  • Growth differentiation factor 15, a potential biomarker and a therapeutic target in myeloproliferative neoplasms
    Meeting Abstract

    Uda, N. R.; Stüdle, C.; Müggler, A.; Ueltschi, O.; Brunner, M.; Silzle, T.; Joachim, W.; Leković, D.; Lee, S. J.; Vannucchi, A. M.; more...
    Swiss Medical Weekly (2023)

    Fulltext@MSK | Save
  • AXL tyrosine kinase mediates escape from type II JAK2 inhibition in myeloproliferative neoplasms
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Ghosh, N.; Passweg, J. R.; Angelillo-Scherrer, A.; Dirnhofer, S.; Levine, R. L.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on chromatin remodeling and MAPK activation and is targetable
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Stivala, S.; Brkic, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Swiss Medical Weekly (2021)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a potent therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Therapeutic resistance to the novel JAK2 inhibitor CHZ868 in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 reduces the fitness of the malignant clone in myeloproliferative neoplasm mice
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J. R.; Tsakiris, D.; Neel, B.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Genetic targeting of ERK1/ERK2 kinases impairs the fitness of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Dirnhofer, S.; Passweg, J. R.; Tsakiris, D. A.; Neel, B. G.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2019)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on targetable MAPK activation and is reversible
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Radimerski, T.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2019)

    Fulltext@MSK | Save
  • Dual JAK2 and ERK1/2 kinase inhibition as a potent corrective approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Jungius, S.; Santopolo, A.; Passweg, J. R.; Tsakiris, D.; Radimerski, T.; Munck, J.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2019)

    Fulltext@MSK | Save

    • E M H Swiss Medical Publishers Ltd – authorized name for: